Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving nearly 38 million members nationally, announced that Mostafa Kamal will succeed Ken Paulus as President and CEO of Prime Therapeutics.
Fresenius Kabi announced the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product.
Fresenius Kabi announced that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs. The Metrodora Institute is an integrated, multidisciplinary medical and research center dedicated to treating neuroimmune axis disorders.
Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease (IBD).
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced the company has received the WHO Emergency Use Listing (EUL) of its COVID-19 vaccine, SKYCovione.
Apex Labs Ltd. a pharmaceutical company transforming the standard of mental health care with clinically proven psilocybin treatments, announces Health Canada
Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, had announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.
Univar Solutions Inc. a leading global solutions provider to users of specialty ingredients and chemicals, today announced the Company has reached an agreement with W. R. Grace & Co. ("Grace") to distribute Grace's SYLOID® FP silica for pharmaceutical and nutraceutical markets in the majority of European countries*.
Blueprint Medicines Corporation announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (ISM). All U.S. patients with ISM now have access to the first and only approved medicine designed to treat their disease.
Abbott announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.